1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (214) 648-8786.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy
Article first published online: 15 NOV 2007
DOI: 10.1002/cncr.23162
Copyright © 2007 American Cancer Society
Additional Information
How to Cite
Shariat, S. F., Karakiewicz, P. I., Ashfaq, R., Lerner, S. P., Palapattu, G. S., Cote, R. J., Sagalowsky, A. I. and Lotan, Y. (2008), Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 112: 315–325. doi: 10.1002/cncr.23162
Publication History
- Issue published online: 4 JAN 2008
- Article first published online: 15 NOV 2007
- Manuscript Accepted: 13 AUG 2007
- Manuscript Revised: 8 AUG 2007
- Manuscript Received: 18 JUN 2007
REFERENCES
- 1,,, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106–130.Direct Link:
- 2,,, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666–675.
- 3,,, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol. 2006; 176: 2414–2422.
- 4,,, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21: 690–696.
- 5,,, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001; 165: 1111–116.
- 6,,,,. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006; 176: 486–492; discussion 491–2.
- 7,,, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007; 51: 137–151.
- 8,,, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol. 1995; 153: 47–52.
- 9,,. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495–499; discussion 499–500.
- 10,,, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145: 459–467.
- 11,,, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006; 12: 6663–6676.
- 12,,, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006; 176: 1354–1361; discussion 1361–1362.
- 13,,, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006; 50: 1254–1260.
- 14,,. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006; 24: 3967–3972.
- 15,,, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998; 58: 1090–104.
- 16,,, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993; 85: 53–59.
- 17,,, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995; 13: 1384–1390.
- 18,,, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer. 1995; 71: 201–205.
- 19,,, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998; 90: 1072–109.
- 20,,, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004; 22: 1014–1024.
- 21,,, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004; 22: 1007–1013.
- 22,,, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res. 1999; 59: 3245–3250.
- 23,,,,,. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol. 2000; 31: 751–760.
- 24,,,. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006; 37: 1568–1576.
- 25,,, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994; 331: 1259–1264.
- 26,,,,. p53 and treatment of bladder cancer. Nature. 1997; 385: 123–125.
- 27,,,,. Cooperative effect of cell cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007; 20: 445–459.
- 28,,, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005; 6: 678–686.
- 29. Bladder cancer clinical trials. Urol Oncol. 2005; 23: 275–279.
- 30,,,,,. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene. 1999; 18: 1197–1203.
- 31,. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515–519.
- 32
- 33. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol. 2003; 170: S6–9; discussion S10.
- 34. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003; 13: 111–116.
- 35,,,,. Evaluating the yield of medical tests. JAMA. 1982; 247: 2543–256.
- 36,,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361–387.Direct Link:
- 37,. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol. 2000; 11: 851–856.
- 38Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006: CD006018.
- 39,,,. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis. 2001; 22: 1693–1699.
- 40,,, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res. 2000; 6: 3552–3559.
- 41,,,. Microarrays as cancer keys: an array of possibilities. J Clin Oncol. 2002; 20: 3165–3175.
- 42,,. Tissue microarrays: bridging the gap between research and the clinic. Expert Rev Proteomics. 2005; 2: 325–336.